RT Journal Article
T1 Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
A1 Dickinson, Michael
A1 Cherif, Honar
A1 Fenaux, Pierre
A1 Mittelman, Moshe
A1 Verma, Amit
A1 Portella, Maria Socorro O
A1 Burgess, Paul
A1 Ramos, Pedro Marques
A1 Choi, Jeea
A1 Platzbecker, Uwe
A1 SUPPORT study investigators, 
AB Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the platelet supportive effects of eltrombopag given concomitantly with azacitidine. International Prognostic Scoring System intermediate-1, intermediate-2, or high-risk MDS patients with baseline platelets
YR 2018
FD 2018-10-10
LK https://hdl.handle.net/10668/27323
UL https://hdl.handle.net/10668/27323
LA en
DS RISalud
RD Apr 7, 2025